How are you counseling HR-proficient ovarian cancer patients about front line PARP inhibitor maintenance?
Community PollStarted
What are your recommendations for HR-proficient advanced ovarian cancer patients after completion of adjuvant therapy with PR/CR?
88 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of Pittsburgh Magee Womens Hospital
Answered on
I think this is a tough decision, but I recommend observation for patients with HR proficient disease. In brief, I don't find a PFS advantage, without a proven OS advantage, enough to justify this long-term, expensive, and not non-toxic treatment.
For BRCA carriers the answer is easier—with SOLO2 (20...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Gynecologic Oncology · Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Answered on
It’s truly exciting to have new FDA approvals in ovarian cancer. Both the PRIMA trial (González-Martín et al, NEJM 2019) and the PAOLO trial (Ray-Coquard et al NEJM 2019) have led to recent approvals for front-line maintenance therapies. When comparing data for the current front-line maintenance opt...
Join for free or sign in to see the full answer